236 related articles for article (PubMed ID: 28258928)
1. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.
De Boeck K; Haarman E; Hull J; Lands LC; Moeller A; Munck A; Riethmüller J; Tiddens H; Volpi S; Leadbetter J; Charlton B; Malfroot A;
J Cyst Fibros; 2017 May; 16(3):380-387. PubMed ID: 28258928
[TBL] [Abstract][Full Text] [Related]
2. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
[TBL] [Abstract][Full Text] [Related]
4. Mannitol dry powder for inhalation: in patients with cystic fibrosis.
Burness CB; Keating GM
Drugs; 2012 Jul; 72(10):1411-21. PubMed ID: 22755516
[TBL] [Abstract][Full Text] [Related]
5. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.
Teper A; Jaques A; Charlton B
J Cyst Fibros; 2011 Jan; 10(1):1-8. PubMed ID: 20888307
[TBL] [Abstract][Full Text] [Related]
6. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
[TBL] [Abstract][Full Text] [Related]
7. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.
Bilton D; Robinson P; Cooper P; Gallagher CG; Kolbe J; Fox H; Jaques A; Charlton B;
Eur Respir J; 2011 Nov; 38(5):1071-80. PubMed ID: 21478216
[TBL] [Abstract][Full Text] [Related]
8. Inhaled mannitol improves lung function in cystic fibrosis.
Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PTP; LeSouëf PN; Shadbolt B; Anderson SD; Charlton B
Chest; 2008 Jun; 133(6):1388-1396. PubMed ID: 18339790
[TBL] [Abstract][Full Text] [Related]
9. Inhaled mannitol for cystic fibrosis.
Nevitt SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2020 May; 5(5):CD008649. PubMed ID: 32358807
[TBL] [Abstract][Full Text] [Related]
10. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial.
Minasian C; Wallis C; Metcalfe C; Bush A
Thorax; 2010 Jan; 65(1):51-6. PubMed ID: 19996349
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis.
Bilton D; Bellon G; Charlton B; Cooper P; De Boeck K; Flume PA; Fox HG; Gallagher CG; Geller DE; Haarman EG; Hebestreit HU; Kolbe J; Lapey A; Robinson P; Wu J; Zuckerman JB; Aitken ML;
J Cyst Fibros; 2013 Jul; 12(4):367-76. PubMed ID: 23234802
[TBL] [Abstract][Full Text] [Related]
12. Inhaled mannitol for the treatment of cystic fibrosis.
Hurt K; Bilton D
Expert Rev Respir Med; 2012 Feb; 6(1):19-26. PubMed ID: 22283575
[TBL] [Abstract][Full Text] [Related]
13. Inhaled Dry Powder Mannitol Treatment in Pediatric Patients with Cystic Fibrosis: Evaluation of Clinical Data in a Real-World Setting.
Duman I; Ünal G; Yilmaz AI; Güney AY; Durduran Y; Pekcan S
Pediatr Allergy Immunol Pulmonol; 2022 Mar; 35(1):19-26. PubMed ID: 35285672
[No Abstract] [Full Text] [Related]
14. A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
Flume PA; VanDevanter DR; Morgan EE; Dudley MN; Loutit JS; Bell SC; Kerem E; Fischer R; Smyth AR; Aaron SD; Conrad D; Geller DE; Elborn JS
J Cyst Fibros; 2016 Jul; 15(4):495-502. PubMed ID: 26852040
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.
Flume PA; Amelina E; Daines CL; Charlton B; Leadbetter J; Guasconi A; Aitken ML
J Cyst Fibros; 2021 Nov; 20(6):1003-1009. PubMed ID: 33715994
[TBL] [Abstract][Full Text] [Related]
16. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
Robinson M; Daviskas E; Eberl S; Baker J; Chan HK; Anderson SD; Bye PT
Eur Respir J; 1999 Sep; 14(3):678-85. PubMed ID: 10543292
[TBL] [Abstract][Full Text] [Related]
17. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
Tarrant BJ; Le Maitre C; Romero L; Steward R; Button BM; Thompson BR; Holland AE
Respirology; 2017 Aug; 22(6):1084-1092. PubMed ID: 28397992
[TBL] [Abstract][Full Text] [Related]
18. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis.
Daviskas E; Anderson SD; Jaques A; Charlton B
Chest; 2010 Apr; 137(4):861-8. PubMed ID: 19880909
[TBL] [Abstract][Full Text] [Related]
19. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).
Konstan MW; VanDevanter DR; Rowe SM; Wilschanski M; Kerem E; Sermet-Gaudelus I; DiMango E; Melotti P; McIntosh J; De Boeck K;
J Cyst Fibros; 2020 Jul; 19(4):595-601. PubMed ID: 31983658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
